stoxline Quote Chart Rank Option Currency Glossary
  
Synlogic, Inc. (SYBX)
1.26  0.046 (3.79%)    06-20 16:00
Open: 1.212
High: 1.26
Volume: 4,568
  
Pre. Close: 1.214
Low: 1.21
Market Cap: 15(M)
Technical analysis
2025-06-20 4:44:12 PM
Short term     
Mid term     
Targets 6-month :  1.51 1-year :  1.76
Resists First :  1.29 Second :  1.51
Pivot price 1.22
Supports First :  1.14 Second :  1.05
MAs MA(5) :  1.23 MA(20) :  1.2
MA(100) :  1.22 MA(250) :  1.37
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  63.5 D(3) :  62
RSI RSI(14): 58.1
52-week High :  1.87 Low :  0.89
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SYBX ] has closed below upper band by 23.6%. Bollinger Bands are 24% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.26 - 1.27 1.27 - 1.27
Low: 1.2 - 1.2 1.2 - 1.21
Close: 1.25 - 1.26 1.26 - 1.27
Company Description

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 19 Jun 2025
Synlogic, Inc. (NASDAQ:SYBX) Short Interest Up 32.1% in May - Defense World

Tue, 12 Nov 2024
Synlogic Reports Third Quarter 2024 Financial Results - GlobeNewswire

Tue, 20 Feb 2024
Synlogic Adopts Limited Duration Stockholders Rights Plan - GlobeNewswire

Sat, 10 Feb 2024
Synlogic Announces Plan to Cease Operations and Reduce Its Workforce by More Than 90% - SynBioBeta

Thu, 08 Feb 2024
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update - Yahoo Finance

Thu, 10 Nov 2022
EX-99.1 - SEC.gov

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 12 (M)
Shares Float 3 (M)
Held by Insiders 11.3 (%)
Held by Institutions 64.7 (%)
Shares Short 29 (K)
Shares Short P.Month 31 (K)
Stock Financials
EPS 0.21
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.12
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -14.1 %
Return on Equity (ttm) 19.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.52
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio 5.72
PEG Ratio 0
Price to Book value 1.12
Price to Sales 0
Price to Cash Flow -0.83
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android